1. Home
  2. SGD vs ENSC Comparison

SGD vs ENSC Comparison

Compare SGD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safe and Green Development Corporation

SGD

Safe and Green Development Corporation

HOLD

Current Price

$0.23

Market Cap

7.4M

Sector

N/A

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.43

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGD
ENSC
Founded
2021
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
6.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SGD
ENSC
Price
$0.23
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.0M
415.8K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,970,752.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2770.15
1.51
52 Week Low
$0.20
$1.26
52 Week High
$3.03
$10.96

Technical Indicators

Market Signals
Indicator
SGD
ENSC
Relative Strength Index (RSI) 21.41 33.84
Support Level $0.74 $1.26
Resistance Level $1.22 $1.69
Average True Range (ATR) 0.12 0.15
MACD -0.09 -0.01
Stochastic Oscillator 2.64 27.97

Price Performance

Historical Comparison
SGD
ENSC

About SGD Safe and Green Development Corporation

Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: